TW202144431A - 工程化抗her2雙特異性蛋白 - Google Patents

工程化抗her2雙特異性蛋白 Download PDF

Info

Publication number
TW202144431A
TW202144431A TW110105842A TW110105842A TW202144431A TW 202144431 A TW202144431 A TW 202144431A TW 110105842 A TW110105842 A TW 110105842A TW 110105842 A TW110105842 A TW 110105842A TW 202144431 A TW202144431 A TW 202144431A
Authority
TW
Taiwan
Prior art keywords
sequence
seq
polypeptide
protein
fused
Prior art date
Application number
TW110105842A
Other languages
English (en)
Chinese (zh)
Inventor
古納斯卡蘭 卡南
度真 金
艾欣 關
家恒 唐
Original Assignee
美商戴納立製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商戴納立製藥公司 filed Critical 美商戴納立製藥公司
Publication of TW202144431A publication Critical patent/TW202144431A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
TW110105842A 2020-02-19 2021-02-19 工程化抗her2雙特異性蛋白 TW202144431A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062978758P 2020-02-19 2020-02-19
US62/978,758 2020-02-19

Publications (1)

Publication Number Publication Date
TW202144431A true TW202144431A (zh) 2021-12-01

Family

ID=77391704

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110105842A TW202144431A (zh) 2020-02-19 2021-02-19 工程化抗her2雙特異性蛋白

Country Status (13)

Country Link
US (1) US20230192887A1 (cg-RX-API-DMAC7.html)
EP (1) EP4181950A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023514371A (cg-RX-API-DMAC7.html)
KR (1) KR20220156526A (cg-RX-API-DMAC7.html)
CN (1) CN115361972A (cg-RX-API-DMAC7.html)
AR (1) AR121384A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021224200A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022016232A2 (cg-RX-API-DMAC7.html)
CA (1) CA3170338A1 (cg-RX-API-DMAC7.html)
IL (1) IL295729A (cg-RX-API-DMAC7.html)
MX (1) MX2022010161A (cg-RX-API-DMAC7.html)
TW (1) TW202144431A (cg-RX-API-DMAC7.html)
WO (1) WO2021168194A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS63818B1 (sr) 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
JP7543290B2 (ja) 2019-02-20 2024-09-02 デナリ セラピューティクス インコーポレイテッド 抗trem2抗体及びその使用方法
CR20230178A (es) 2020-10-14 2023-07-26 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas
IL311003A (en) 2021-08-25 2024-04-01 Denali Therapeutics Inc Anti-2HER antibodies and methods of using them
US20240392035A1 (en) * 2021-08-25 2024-11-28 Denali Therapeutics Inc. Engineered anti-her2 bispecific proteins
CN120077064A (zh) * 2022-08-05 2025-05-30 詹森生物科技公司 用于治疗脑肿瘤的转铁蛋白受体结合蛋白
EP4565331A1 (en) * 2022-08-05 2025-06-11 Janssen Biotech, Inc. Cd98 binding constructs for treating brain tumors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005047327A2 (en) * 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
US9101674B2 (en) * 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
LT3074424T (lt) * 2013-11-27 2025-05-26 Zymeworks Bc Inc. Bispecifiniai antigeną surišantys konstruktai, nukreipti į her2
WO2015095412A1 (en) * 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
JP6510532B2 (ja) * 2013-12-20 2019-05-08 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性her2抗体及び使用方法
CA2943299A1 (en) * 2014-04-11 2015-10-15 Medimmune, Llc Bispecific her2 antibodies
US10717783B2 (en) * 2014-12-22 2020-07-21 Zeren Gao Bispecific tetravalent antibodies and methods of making and using thereof
JP7021955B2 (ja) * 2015-06-24 2022-03-03 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Her2及び血液脳関門受容体に特異的な三重特異性抗体及び使用方法
CA3053381A1 (en) * 2017-02-17 2018-08-23 Denali Therapeutics Inc. Engineered polypeptides
WO2019032955A1 (en) * 2017-08-10 2019-02-14 Denali Therapeutics Inc. MODIFIED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
RU2018111298A (ru) * 2018-03-29 2019-10-01 Закрытое Акционерное Общество "Биокад" Биспецифическое антитело, которое специфично связывается с IV и II cубдоменами внеклеточного домена HER2 человека
EP3840781A1 (en) * 2018-08-22 2021-06-30 Denali Therapeutics Inc. Anti-her2 polypeptides and methods of use thereof

Also Published As

Publication number Publication date
EP4181950A4 (en) 2024-07-17
KR20220156526A (ko) 2022-11-25
MX2022010161A (es) 2022-11-07
JP2026086568A (ja) 2026-05-26
IL295729A (en) 2022-10-01
US20230192887A1 (en) 2023-06-22
CA3170338A1 (en) 2021-08-26
EP4181950A1 (en) 2023-05-24
AU2021224200A1 (en) 2022-09-08
BR112022016232A2 (pt) 2022-11-16
CN115361972A (zh) 2022-11-18
AR121384A1 (es) 2022-06-01
WO2021168194A1 (en) 2021-08-26
JP2023514371A (ja) 2023-04-05

Similar Documents

Publication Publication Date Title
JP7818042B2 (ja) 抗her2ポリペプチド及びそれらの使用の方法
US20230192887A1 (en) Engineered anti-her2 bispecific proteins
EP3227328B1 (en) Domain-exchanged antibody
CN103703026B (zh) 单特异性和双特异性抗igf-1r和抗erbb3抗体
JP7793774B2 (ja) メソテリン結合タンパク質及びその使用
WO2019068758A1 (en) MODIFIED CYSTEINE MOLECULES BINDING TO ANTIGEN
CN111448217A (zh) 双特异性抗原结合构建体
US20260109781A1 (en) Anti-her2 antibodies and methods of use thereof
JP2026505164A (ja) 抗cmet抗体及びその使用方法
CN120530135A (zh) 抗b7h3抗体和使用方法
WO2024193450A1 (en) Anti-b7h3 antibodies and methods of use
JP2025524899A (ja) メソテリン結合タンパク質及びその使用
US20240392035A1 (en) Engineered anti-her2 bispecific proteins
HK40084724A (en) Engineered anti-her2 bispecific proteins
HK40110414A (en) Anti-her2 antibodies and methods of use thereof
JP2023551907A (ja) 腫瘍関連抗原及びcd3結合タンパク質、関連する組成物、及び方法